Table 3.
Univariate and multivariable analyses of the prognostic factors.
| Characteristics | Total (n = 843) N (%) |
Univariable Analysis | Multivariable Analysis | ||
|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | ||
| Age at diagnosis | |||||
| <60 | 426 (50.5) | 1 | |||
| ≥60 | 417 (49.5) | 1.014 (0.626–1.645) | 0.954 | ||
| ER status | |||||
| Negative | 286 (33.9) | 1 | 1 | ||
| Positive | 476 (56.5) | 0.398 (0.233–0.681) | 0.001 | 0.399 (0.233–0.684) | 0.001 |
| Unknown | 81 (9.6) | 1.039 (0.513–2.104) | 0.915 | 1.123 (0.551–2.287) | 0.750 |
| PR status | |||||
| Negative | 410 (48.6) | 1 | |||
| Positive | 334 (39.6) | 0.483 (0.271–0.861) | 0.014 | ||
| Unknown | 99 (11.7) | 0.873 (0.424–1.796) | 0.711 | ||
| HER-2 status | |||||
| Negative | 266 (31.6) | 1 | 0.847 | ||
| Positive | 102 (12.1) | 0.809 (0.299-2.194) | 0.678 | ||
| Unknown | 475 (56.3) | 0.854 (0.474–1.537) | 0.598 | ||
| Grade | |||||
| I–II | 48 (5.7) | 1 | |||
| III–IV | 163 (19.3) | 1.972 (0.586–6.641) | 0.273 | ||
| Unknown | 632 (75.0) | 1.169 (0.363–3.77) | 0.793 | ||
| pN | |||||
| N1 | 504 (59.8) | 1 | 1 | ||
| N2 | 165 (19.6) | 2.505 (1.298–4.834) | 0.006 | 2.104 (1.083–4.09) | 0.028 |
| N3 | 174 (20.6) | 4.765 (2.706–8.392) | <0.001 | 2.662 (1.438–4.929) | 0.002 |
| Number of regional LNs examined | |||||
| <6 | 218 (25.9) | 1 | |||
| ≥6, <10 | 97 (11.5) | 0.574 (0.232–1.415) | 0.228 | ||
| ≥10 | 528 (62.6) | 0.648 (0.383–1.096) | 0.105 | ||
| PLNR | |||||
| <0.50 | 502 (59.5) | 1 | 1 | ||
| ≥0.50 | 341 (40.5) | 5.07 (2.887–8.905) | <0.001 | 3.584 (1.943–6.614) | <0.001 |
| Breast surgery | |||||
| Mastectomy | 322 (38.2) | 1 | |||
| Breast-conserving surgery | 92 (10.9) | 1.047 (0.614–1.783) | 0.867 | ||
| No | 429 (50.9) | 1.512 (0.719–3.178) | 0.275 | ||
| Radiotherapy | |||||
| Yes | 455 (54.0) | 1 | |||
| No | 388 (46.0) | 1.241 (0.766–2.011) | 0.381 | ||
| Chemotherapy | |||||
| Yes | 636 (75.4) | 1 | |||
| No | 207 (24.6) | 0.989 (0.556–1.759) | 0.970 | ||
Abbreviations: HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor-2; PLNR, positive lymph node ratio; LN, lymph node.